Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves

Karen W. Jeng, John Wilgucki, Scott Halperin, William J. Feuer, Howard F. Fine, Daniel Roth, Jonathan L. Prenner

Research output: Contribution to journalArticle

13 Scopus citations


PURPOSE:: To evaluate the presence of cognitive biases among retina physicians when recommending treatment options for exudative age-related macular degeneration. METHODS:: Two random samples of retina specialists were surveyed regarding their treatment and dosing regimen choices among three anti-vascular endothelial growth factor biologics (aflibercept, bevacizumab, and ranibizumab). One group was asked to provide recommendations for a standardized hypothetical patient with exudative age-related macular degeneration, whereas the other group was asked to provide recommendations as if they themselves were the standardized hypothetical patient with exudative age-related macular degeneration. RESULTS:: Two hundred and twenty-six respondents (28.3%) completed the survey and were divided equally between the survey groups. For patients, most physicians recommended bevacizumab (52.2%), but when choosing for themselves, physicians were divided equally among all 3 biologics (P = 0.011). The results were influenced by geographical location of the physician but not by the gender or length of practice. Furthermore, physicians differed in dosing regimen selection with the majority (73%) choosing treat and extend for patients, whereas only 63% selected this regimen for themselves (P = 0.004). CONCLUSION:: When considering cases of exudative age-related macular degeneration, physicians would recommend different treatments for themselves than they would for a patient.

Original languageEnglish (US)
Pages (from-to)1796-1801
Number of pages6
Issue number9
StatePublished - Sep 2014



  • Aflibercept
  • Anti-VEGF therapy
  • Bevacizumab
  • Cognitive biases
  • Exudative age-related macular degeneration
  • Physician treatment preferences
  • Ranibizumab
  • Treatment choices for exudative AMD

ASJC Scopus subject areas

  • Ophthalmology

Cite this